Estats Units - anglès - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - pacerone® is indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. risk summary available data from postmarketing reports and published case series indicate that amiodarone use in pregnant women may increase the risk for fetal adverse effects including neonatal hypo- and hyperthyroidism, neonatal bradycardia, neurodevelopmental abnormalities, preterm birth and fetal growth restriction. amiodarone and its metabolite, desethylamiodarone (dea), cross the placenta. untreated underlying arrhythmias, including ventricular arrhythmias, during pregnancy pose a risk to the mother and fetus (see clinical considerations). in animal studies, administration of amiodarone to rabbits, rats, and mice during organogenesis resulted in embryofetal toxicity at doses less than the maximum

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - meningococcal polysaccharide 48ug (4 µg of each of groups a, c, y & w-135, each separately conjugated to diphtheria toxoid, 48 µg total) - solution for injection - 4 µg each/0.5 ml - active: meningococcal polysaccharide 48ug (4 µg of each of groups a, c, y & w-135, each separately conjugated to diphtheria toxoid, 48 µg total) excipient: dibasic sodium phosphate monobasic sodium phosphate sodium chloride water for injection - menactra vaccine is indicated for active immunisation in individuals from 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n. meningitidis serogroups a, c, y and w-135. menactra vaccine is not indicated for the prevention of meningitis caused by other microorganisms or for the prevention of invasive meningococcal disease caused by n meningitidis serogroup b. menactra vaccine is not indicated for treatment of meningococcal infections. menactra vaccine is not indicated for immunisation against diphtheria.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - meningococcal oligosaccharide group y, quantity: 5 microgram; meningococcal oligosaccharide group c, quantity: 5 microgram; diphtheria crm197 protein, quantity: 16 microgram; meningococcal oligosaccharide group w135, quantity: 5 microgram - injection, solution - excipient ingredients: sodium chloride; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate - menveo is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w-135 and y. the use of this vaccine should be in accordance with official recommendations.

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - hydrocortisone acetate; clotrimazole - cutaneous cream - 10mg/1gram ; 10mg/1gram

Tanzània - anglès - Tanzania Medicinces & Medical Devices Authority

crown healthcare (t) ltd, tanzania - sample cups -

Estats Units - anglès - NLM (National Library of Medicine)

merci handy corporation - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - - for handwashing to decrease bacteria on the skin

Estats Units - anglès - NLM (National Library of Medicine)

merci handy corporation - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - - for handwashing to decrease bacteria on the skin

Estats Units - anglès - NLM (National Library of Medicine)

merci handy corporation - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - - for handwashing to decrease bacteria on the skin

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - meningococcal polysaccharide group w135, quantity: 10 microgram; meningococcal polysaccharide group c, quantity: 10 microgram; meningococcal polysaccharide group a, quantity: 10 microgram; meningococcal polysaccharide group y, quantity: 10 microgram - injection, solution - excipient ingredients: sodium acetate; tetanus toxoid; sodium chloride; water for injections - menquadfi is indicated for active immunisation for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w and y.,the use of menquadfi should be in accordance with official recommendations.

Estats Units - anglès - NLM (National Library of Medicine)

upsher-smith laboratories, llc - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - jantoven® is indicated for: - prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). - prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. - reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use warfarin sodium has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. jantoven is contraindicated in: - pregnancy jantoven is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precautions (5.7) and